| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2024 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 1,207 | $140.78 | $169,926.77 | -3.1% | -1.6% | +9.7% | |
| Jan 30, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 76,215 | $645.22 | $49,175,200.12 | - | +14.3% | +24.7% | |
| Jan 30, 2024 | EOLS Evolus, Inc. | Parschauer Karah Herdman77 | Director | Sell | 11,931 | $13.14 | $156,732.77 | -27.6% | -9.7% | +12.3% | |
| Jan 29, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 54,032 | $645.07 | $34,854,422.24 | - | +14.3% | +24.8% | |
| Jan 29, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew48 | Chief Executive Officer | Sell | 195,728 | $9.08 | $1,777,481.01 | -55.8% | +39.1% | +249.7% | |
| Jan 25, 2024 | ETST Earth Science Tech, Inc. | Sanchez Yovan Arturo | Director | Buy | 50,000 | $0.06 | $3,000.00 | +11.1% | - | - | |
| Jan 24, 2024 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd70 | 10% Owner | Sell | 3,703,703 | $8.10 | $29,999,994.30 | -49.7% | -8.9% | -12.0% | |
| Jan 24, 2024 | BSPK Bespoke Extracts, Inc. | Feinsod Michael | CEO | Buy | 96,500 | $0.06 | $5,710.00 | +0.4% | - | - | |
| Jan 23, 2024 | ANIP Ani Pharmaceuticals Inc | Shanmugam Muthusamy59 | Head Of R&D, Coo-novitium Ops | Sell | 25,216 | $56.17 | $1,416,466.08 | -0.9% | +15.9% | +2.7% | |
| Jan 22, 2024 | AMRN Amarin Corp Plc\uk | Holt Patrick | President And CEO | Buy | 14,426 | $1.09 | $15,724.34 | +4.8% | -24.7% | -50.5% | |
| Jan 22, 2024 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 10,000 | $139.86 | $1,398,553.00 | -21.8% | -4.4% | +4.3% | |
| Jan 18, 2024 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $218.72 | $1,312,322.33 | -3.1% | +7.4% | +63.8% | |
| Jan 18, 2024 | ZTS Zoetis Inc. | Lagano Roxanne70 | Executive Vice President | Sell | 923 | $191.43 | $176,689.89 | -5.0% | -20.2% | -12.9% | |
| Jan 18, 2024 | ANIP Ani Pharmaceuticals Inc | Shanmugam Muthusamy59 | Head Of R&D, Coo-novitium Ops | Sell | 24,784 | $55.29 | $1,370,305.20 | -0.9% | +17.8% | +5.2% | |
| Jan 17, 2024 | TLRY Tilray Brands, Inc. | Faltischek Denise M | Chief Strategy Officer | Buy | 10,000 | $2.05 | $20,500.00 | +3.5% | -11.2% | -42.7% | |
| Jan 16, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 1,180 | $645.60 | $761,805.60 | - | +18.3% | +17.7% | |
| Jan 16, 2024 | AVDL Avadel Pharmaceuticals Plc | McHugh Thomas S73 | Chief Financial Officer | Buy | 2,000 | $14.50 | $29,000.00 | +2.5% | +14.2% | -45.2% | |
| Jan 16, 2024 | TLRY Tilray Brands, Inc. | Gendel Mitchell | Global General Counsel | Buy | 7,200 | $1.98 | $14,256.00 | +3.8% | -14.8% | -43.5% | |
| Jan 16, 2024 | COLL Collegium Pharmaceutical, Inc | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 23,560 | $32.28 | $760,519.16 | -17.5% | +8.6% | +1.9% | |
| Jan 16, 2024 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 341 | $56.01 | $19,099.41 | -0.6% | +9.0% | +69.0% | |
| Jan 12, 2024 | TLRY Tilray Brands, Inc. | Gendel Mitchell | Global General Counsel | Buy | 5,400 | $1.87 | $10,098.00 | +2.9% | +1.6% | -34.2% | |
| Jan 12, 2024 | TLRY Tilray Brands, Inc. | Simon Irwin D | President And CEO | Buy | 53,700 | $1.88 | $100,956.00 | +2.7% | +1.6% | -34.2% | |
| Jan 12, 2024 | ANIP Ani Pharmaceuticals Inc | Cook Meredith49 | Sr. VP, General Counsel &Sec. | Sell | 250 | $56.43 | $14,107.50 | -0.7% | +20.0% | -3.0% | |
| Jan 12, 2024 | TLRY Tilray Brands, Inc. | Merton Carl A | Chief Financial Officer | Buy | 20,000 | $1.87 | $37,400.00 | New | +1.6% | -34.2% | |
| Jan 11, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 12,344 | $634.13 | $7,827,685.81 | - | +19.9% | +25.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.